Navigation Links
Jeffrey Epstein, Science Financier, Changes the Course of Evolution at Harvard
Date:6/12/2013

NEW YORK, June 12, 2013 /PRNewswire/ -- Ten years ago the Program for Evolutionary Dynamics was founded at Harvard with a $30 million dollar grant from a financier called Jeffrey Epstein. Since then, the Program, under the direction of Martin Nowak, a professor of Mathematics and Biology at Harvard, has changed the way in which evolution is studied and utilized.

The Program is the first to study the evolution of micro biology with the use of mathematics. It is also the first to develop mathematical models of how cancer cells evolve as well as various bacteria and viruses such as HIV. The creation of such models has led to key discoveries in combatting diseases of all kinds.

In 2012 for example, the Program developed the first mathematical model of how colon cancer cells become immune to inhibitor therapy. The research showed how the KRAS gene is not activated from inhibitor drugs, making cells resistant, but rather a small percentage of cancer cells with an inherantly activated KRAS gene are immune from the start and evolve to predominance as other cancer cells are destroyed by the inhibitor drug. The discovery was critical because instead of applying drugs in sequence to fight resistance, using a cocktail of inhibitor drugs to capture both activated KRAS gene cells and those without, came into focus.

In 2010, the Program published a study showing that most solid tumors contain 40 to 100 genetic mutations, but on average only 5 to 15 actually drive tumor growth. The findings highlighted the importance of targeting only a minority of tumor cells for effective inhibitor treatment.

"Mathematics in evolutionary biology is an exciting new field," Jeffrey Epstein remarked, whose foundation supports cutting edge science across the United States. "It reveals patterns that are otherwise hard to detect."

In addition to disease analysis, the Program has advanced critical evolutionary concepts, including "natural cooperation", quantitative analysis for the evolution of language, game theory, pre-life theory and spatial selection.

Jeffrey Epstein is the founder of the Jeffrey Epstein VI Foundation. He sits on the board for the Mind, Brain and Behavior Committee at Harvard University.

http://www.jeffreyepstein.org


'/>"/>
SOURCE Jeffrey Epstein VI Foundation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Carnegie Mellons Jeffrey Hollinger Leads Research Team Developing New Tools To Ease Pain of Combat Injuries
2. A Genetic Approach For Crohns And Colitis Disease Is Financed By The Jeffrey Epstein VI Foundation
3. Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman
4. Stephen Epstein, MD To Head Scientific & Medical Advisory Board For Stemedica’s Cardiology Division
5. Computer Review Monitors Science and Technology Parks
6. Bayer Anniversary Tour: Hands-on Science for All
7. MEI Pharma Adds Former YM BioSciences CEO Nick Glover To Board Of Directors
8. BioDelivery Sciences Announces NDA Submission for BUNAVAIL on Track Following Positive Pre-NDA Meeting with FDA
9. Leveraging an Academic-Industry Partnership for Commercial Success, New Life Science Webinar Hosted By Xtalks
10. Endpoint Based Protocol Development: A Central Laboratory Perspective + Microbiology Case Study, New Life Science Webinar Hosted by Xtalks
11. Caris Life Sciences ASCO Presentation Highlights the Utility of Molecular Profiling for the Management of Rare and Aggressive Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb. 23, 2017  Imanis Life ... product line of oncolytic vaccinia viruses for virotherapy ... as part of Genelux,s proprietary, vaccinia virus-based technology ... excited to enter into a partnership with Genelux ... oncolytic vaccinia viruses for use in research," said ...
(Date:2/23/2017)... ... 23, 2017 , ... The Greater Gift Initiative, Inc , (GGI) a ... Research . GGI's mission is to advance global health and highlight the greater good ... honor of each clinical trial volunteer. The vision of GGI is to serve as ...
(Date:2/22/2017)... , Feb. 22, 2017  Aratana Therapeutics, Inc. (NASDAQ: ... and commercialization of innovative biopharmaceutical products for companion animals, will ... at 8:30 a.m. ET to discuss financial results from the ... Interested participants and investors may access the ... ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... the leading medical education provider of women’s health, primary care, and specialty ... Council for Continuing Medical Education (ACCME). ACCME’s Accreditation with Commendation is a ...
Breaking Biology Technology:
(Date:2/8/2017)... 8, 2017 About Voice Recognition Biometrics Voice ... it against a stored voiceprint template. Acoustic features ... and tone are compared to distinguish between individual ... as most PCs already have a microphone and ... recognition biometrics are most likely to be deployed ...
(Date:2/8/2017)... Report Highlights ... The global synthetic-biology market reached nearly $3.9 billion in ... a compound annual growth rate (CAGR) of 24.0% through 2021. ... for synthetic biology. - Analyses of global market trends, with ... annual growth rates (CAGRs) through 2021. - Coverage of core ...
(Date:2/8/2017)... Report Highlights The global biosurgery market should ... 2016 at a compound annual growth rate (CAGR) of ... An overview of the global market for biosurgery. - ... and 2016, and projections of compound annual growth rates ... the basis of product type, source, application, and region. ...
Breaking Biology News(10 mins):